41 - Education, entertainment, sporting and cultural services
Goods & Services
Providing information in the field of economics (terms
considered too vague by the International Bureau - Rule 13
(2) (b) of the Regulations). Educational services, namely, conducting classes in the
field of economics at the university undergraduate and
graduate level and providing publications, namely,
educational materials in connection therewith; educational
services, namely, conducting classes in the field of
economics at the university undergraduate and graduate level
and providing course materials in connection therewith;
providing educational course materials for high school
classes in the field of economics; providing training in the
field of economics and distribution of educational materials
in connection therewith for high school teachers.
2.
L-PAG DERIVATIVES FOR TREATMENT OF SLEEP DISORDERED BREATHING (SDB)
Described herein are novel γ- and δ-propargyl carboxylic acids and esters. The novel compositions are antagonists of CSE and may be used to modulate of the activity of the carotid body, therefore providing therapeutic benefits for sleep-related breathing disorders and related conditions.
A61K 31/197 - Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
A61K 31/198 - Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
A61K 31/216 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
A61K 31/221 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
A61K 31/381 - Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61P 11/00 - Drugs for disorders of the respiratory system
C07C 229/30 - Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and unsaturated
C07D 277/30 - Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
C07D 333/24 - Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
3.
MODIFICATION OF LITHIUM ION ELECTRODE MATERIALS VIA ATOMIC LAYER DEPOSITION TECHNIQUES
A method for coating of lithium ion electrode materials via atomic layer deposition. The coated materials may be integrated in part as a dopant in the electrode itself via heat treatment forming a doped lithium electrode.
C23C 16/455 - Chemical coating by decomposition of gaseous compounds, without leaving reaction products of surface material in the coating, i.e. chemical vapour deposition [CVD] processes characterised by the method of coating characterised by the method used for introducing gases into the reaction chamber or for modifying gas flows in the reaction chamber
H01M 4/02 - Electrodes composed of, or comprising, active material
H01M 4/36 - Selection of substances as active materials, active masses, active liquids
H01M 4/48 - Selection of substances as active materials, active masses, active liquids of inorganic oxides or hydroxides
H01M 4/525 - Selection of substances as active materials, active masses, active liquids of inorganic oxides or hydroxides of nickel, cobalt or iron of mixed oxides or hydroxides containing iron, cobalt or nickel for inserting or intercalating light metals, e.g. LiNiO2, LiCoO2 or LiCoOxFy
H01M 10/0525 - Rocking-chair batteries, i.e. batteries with lithium insertion or intercalation in both electrodesLithium-ion batteries
The University of North Carolina at Chapel Hill (USA)
Inventor
Pandarinath, Chethan
Zhu, Feng
Kaufman, Matthew Tyler
Sedler, Andrew Robert
Giovannucci, Andrea
Abstract
The present disclosure provides novel training systems and methods for recurrent neural network models. One such method comprises obtaining a first sequence of sparse input data as training data; augmenting the first sequence of sparse input data by zero-filling missing input points; training the recurrent neural network model using the augmented sequence of sparse input data to obtain a trained recurrent neural network model, and applying new data as an input to the trained recurrent neural network model, wherein the new data comprises a second sequence of sparse input data to obtain a corresponding output data sequence.
The present disclosure is generally directed to nanoparticle-containing media exhibiting enhanced optical transparency, related nanoparticles, and associated systems and methods. In certain embodiments, the refractive index (RI) of a nanoparticle comprising thermochromic material (such as VO2) can be made closer to the refractive index of a surrounding medium by tethering a material (such as a gradient copolymer) to the core region of the nanoparticle to modify the refractive index of the nanoparticle. Modifying the refractive index of the nanoparticle to be closer to the refractive index of the medium that contains the nanoparticle can render the nanoparticle-containing medium (also referred, to herein as a composite) more transparent to various wavelengths of electromagnetic radiation while imparting thermochromic properties to the nanoparticle-containing medium.
C09C 3/10 - Treatment with macromolecular organic compounds
C09D 5/29 - Coating compositions, e.g. paints, varnishes or lacquers, characterised by their physical nature or the effects producedFilling pastes for multicolour effects
C09D 7/62 - Additives non-macromolecular inorganic modified by treatment with other compounds
C09K 9/00 - Tenebrescent materials, i.e. materials for which the range of wavelengths for energy absorption is changed as a result of excitation by some form of energy
6.
COMPOSITIONS AND METHODS RELATED TO PROTEIN A (SpA) VARIANTS
The present invention concerns methods and compositions for treating or preventing a bacterial infection, particularly infection by a Staphylococcus bacterium. The invention provides methods and compositions for stimulating an immune response against the bacteria. In certain embodiments, the methods and compositions involve a non-toxigenic Protein A (SpA) variant.
C07K 14/31 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
A61K 39/00 - Medicinal preparations containing antigens or antibodies
The present disclosure relates to a biomaterial matrix having a live bacteria impregnated hydrogel, using the biomaterial matrix to treat epidermal inflammation of an animal, and wearable electronic devices having the biomaterial matrix installed thereon.
Board of Trustees of Northern Illinois University (USA)
UChicago Argonne, LLC (USA)
Inventor
Xu, Tao
Liu, Di-Jia
Abstract
A method of producing ethanol by electrocatalytic reduction of carbon dioxide, comprises reducing carbon dioxide in an aqueous electrolyte on an electrocatalyst with electricity. The electrocatalyst is exposed to a magnetic field of at least 400 Gauss, the electrocatalyst comprises at least one paramagnetic material, and an amount of ethanol produced by the reducing is greater than an amount of ethanol produced without the magnetic field. Also described is a system for electrocatalytic reduction of carbon dioxide, which comprises (a) and electrocatalyst, containing (i) copper and (ii) copper oxide, C60 and/or neodymium; (b) an aqueous electrolyte, in contact with the electrocatalyst; (c) a counter electrode, in ion-conductive contact with the electrocatalyst; (d) a magnet, for providing a magnetic field of at least 400 Gauss to the electrocatalyst; and (e) a power source, electronically connected to the electrocatalyst and the counter electrode.
C25B 11/091 - Electrodes formed of electrocatalysts on a substrate or carrier characterised by the electrocatalysts material consisting of at least one catalytic element and at least one catalytic compoundElectrodes formed of electrocatalysts on a substrate or carrier characterised by the electrocatalysts material consisting of two or more catalytic elements or catalytic compounds
9.
TRANS-VACCENIC ACID (TVA) AND DERIVATIVES THEREOF IN T CELL-BASED CANCER THERAPIES
Provided herein are compositions and methods for stimulating T-cell-based anti-tumor immunity by administration of trans-vaccenic acid (TVA), an active derivative thereof, or an inhibitor of GPR43 expression or activity. In particular embodiments, TVA, a TVA derivative, or an inhibitor of GPR43 expression or activity is administered to boost an endogenous T-cell response and/or is co-administered with a T-cell-based therapy, such as immune checkpoint blockade therapies, CAR-T therapies, monoclonal antibody therapies, bispecific T-cell engagers therapies, etc.
A61K 31/201 - Carboxylic acids, e.g. valproic acid having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid having one or two double bonds, e.g. oleic or linoleic acid
A61K 31/198 - Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
A61K 31/202 - Carboxylic acids, e.g. valproic acid having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid having three or more double bonds, e.g. linolenic acid
A61K 31/397 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 40/11 - T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cellsLymphokine-activated killer [LAK] cells
The current disclosure provides for methods for diagnosing, prognosing, and treating cerebral cavernous malformations (CCMs). Also provided are methods for determining the efficacy of therapeutic treatments for CCM, such as those that may be in a clinical trial setting or administered by a health care professional. Accordingly, aspects of the disclosure relate to method for treating cerebral cavernous malformations (CCMs) in a subject, the method comprising administering a therapy to a subject determined to have differential expression of one or more biomarkers selected from the biomarkers listed in Tables S1-S8 and S13 in a biological sample from the subject. Further aspects relate to A method for treating cerebral cavernous malformations (CCMs) in a subject, the method comprising administering a therapy to a subject determined to have differential expression of one or more biomarkers selected from let-7e-5p, miR-93-5p, miR-20b-5p, miR-128-3p, miR-9-5p, IL-10, Tsp-2, IL-2, and TNER1.
C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
C12N 15/115 - Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
11.
LASER IGNITER, METHOD FOR IGNITING HIGH PRESSURE AND DILUTE FUEL-OXIDIZER MIXTURES
The invention provides method for igniting pressurized fuel, the method comprising placing fuel into a combustion chamber; mixing the fuel with supercritical carbon dioxide and oxidizer to create a mixture; and contacting the fuel-air mixture with a laser, whereby the laser is pointed to a first point within the chamber. Also provided is a laser ignitor for carbon dioxide combustors, the ignitor comprising: an elongated housing capable of varying in length, the housing having a first proximal end and a second distal end; a laser head in close spatial relationship to the proximal end, wherein the laser head generates a first laser beam; a seal at the distal end that is optically transparent to the laser beam and physically opaque to combustion contaminants; an algorithm for directing the first beam to a first point within a combustion chamber for a first period of time; and an algorithm for directing a second laser beam to a second point within the combustion chamber for a second period of time.
A molecular-spin qubit includes a molecular color center having a ground state and an excited state. The ground state has non-zero spin with at least first and second sublevels. The molecular-spin qubit also includes a host matrix that is non-isostructural with the molecular color center. The molecular color center is diluted in the host matrix. An optical transition between the ground and excited states lies in the optical region of the electromagnetic spectrum. A spin transition between the first and second sublevels lies in the microwave or millimeter-wave regions of the electromagnetic spectrum. Each of the first and second sublevels is first-order insensitive to magnetic fields near zero magnetic. The molecular color center and host matrix may each be formed from strong-field ligands bound to a metal-atom center. One example of the molecular-spin qubit is Cr(IV)(o-toyl)4 diluted in a host matrix of Sn(IV)(4-fluoro-2-methylphenyl)4.
Stretchable light-emitting polymers are provided. Stretchable organic light-emitting diodes including the stretchable light-emitting polymers are further provided.
H10K 50/11 - OLEDs or polymer light-emitting diodes [PLED] characterised by the electroluminescent [EL] layers
C08F 26/06 - Homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen by a heterocyclic ring containing nitrogen
An optical cavity includes a plurality of mirrors that reflect light along a closed path. First and second mirrors of the plurality of mirrors define an optical axis therebetween. The optical cavity includes first and second lenses located between the first and second mirrors along the optical axis. A mode of the optical cavity has a waist located between the first and second intracavity lenses. Small values of the waist (e.g., <10 microns) produce large cooperativities that relax requirements for the cavity finesse (i.e., reflectivity of the mirrors). The mirrors may be retroreflecting to create a Fabry-Perot cavity. Alternatively, the first and second mirrors may define one segment of a ring cavity. The optical cavity may be used to trap, read, entangle, and drive nonlinear emitters (e.g., atoms, color centers, quantum dots) located near the waist.
Provided herein are pharmaceutical compositions and dietary supplements comprising vanadyl sulfate (VS) and method of use thereof for the induction of cell death in senescent cells. In particular. VS compositions find use in clearance of age-related and/or therapy-induced senescent cells and reduction/elimination of senescence associated secretory phenotype (SASP)-induced inflammatory environments in subjects. and therefore in the treatment/prevention of age-related conditions and/or cancer.
Described herein are polymersomes (PSs) as a delivery platform that display enhanced macromolecular encapsulation efficiency with facile, streamlined processing. The formulations herein demonstrate rapid assembly of near-monodisperse PSs without organic solvents to circumvent purification issues. This is achieved through two design principles: 1) temperature responsive PS assembly and 2) affinity-driven payload encapsulation. The BCPs are solubilized in aqueous buffer when refrigerated (4 °C) but self-assemble at room temperature (20 °C) into homogeneous PSs. This is achieved by incorporating polymers segments with a lower critical solution temperature (LCST) below room temperature but above the freezing point of water. BCPs are dissolved alongside a hydrophilic payload, and their uniform self-assembly bypasses solvent and size-exclusion purifications.
C08G 81/00 - Macromolecular compounds obtained by interreacting polymers in the absence of monomers, e.g. block polymers
C08L 33/06 - Homopolymers or copolymers of esters of esters containing only carbon, hydrogen, and oxygen, the oxygen atom being present only as part of the carboxyl radical
A61K 47/60 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
Systems and methods for delivering a drug to a patient's kidney. The present systems comprise a urethral catheter and a ureteral catheter sized to fit through the urethral catheter. The urethral catheter includes a balloon configured to be inflated in the patient's bladder to retain the urethral catheter in the patient's urethra. The ureteral catheter includes a balloon configured to be inflated in the patient's ureter and/or kidney while a distal end of the ureteral catheter is disposed in the patient's kidney. The ureteral catheter balloon can help retain liquid in the kidney to enable expanded contact areas with kidney tissues and extended dwell times (e.g., periods of exposure) of the drug in the kidney. The balloons also help retain the catheters in the patient's urinary tract, such that the catheter system can be used to deliver a drug to the patient's intermittently or periodically over a period of days or weeks.
A61M 31/00 - Devices for introducing or retaining media, e.g. remedies, in cavities of the body
A61M 1/00 - Suction or pumping devices for medical purposesDevices for carrying-off, for treatment of, or for carrying-over, body-liquidsDrainage systems
18.
DIAMOND MATERIALS WITH REDUCED HYDROGEN-PASSIVATED DEFECTS AND ASSOCIATED FABRICATION METHODS
The present disclosure includes an arm support for supporting a patient's arm during a procedure, such as a cardiac catheterization procedure. Some arm supports include a unitary body defining: a lower portion, an upper portion, a first end, a second end, a proximal side, and a distal side of the arm support, where the lower portion of the unitary body defines a mount configured to be coupled to a patient support, and where the upper portion of the unitary body defines a support surface extending between the first and second ends, where the support surface is shaped to support a patient's arm.
Disclosed are compositions and methods useful for cancer treatment. The composition and methods include overexpressing BAMBI in a population of immune cells, such as myeloid-derived suppressor cells, in order to improve the immune cells immunogenic and/or anti-tumor effects. Also disclosed are compositions and methods for determining responsiveness to a radiotherapy and/or immunotherapy.
A61K 35/15 - Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cellsMyeloid precursor cellsAntigen-presenting cells, e.g. dendritic cells
A61K 9/00 - Medicinal preparations characterised by special physical form
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C12N 5/078 - Cells from blood or from the immune system
21.
COMPOSITIONS, KITS, AND METHODS FOR ASSESSING MICROBIOME HEALTH
The present disclosure provides compositions and methods related to microbiome health. In particular, the present disclosure provides novel compositions, kits, and methods for treating and/or monitoring the microbiome health of a subject using metabolic biomarkers.
THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (USA)
UNIVERSITY OF CHICAGO (USA)
LEIDOS BIOMEDICAL RESEARCH, INC. (USA)
SCHRODINGER, INC. (USA)
CURIA GLOBAL, INC. (USA)
Inventor
Stott, Gordon
Green, Neal
Eckert, Mark
Allega, Maria Francesca
White, Andrew
Wolf, Mark Allan
Abstract
NN-methyltransferase (NNMT) which have a triazolone-piperidine scaffold. The NNMT inhibitors are useful for treating tumors and cancers, metabolic disorders and liver disorders.
C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
23.
SYSTEMS AND METHODS FOR OPTIMIZED PULSES FOR CONTINUOUS QUANTUM GATE FAMILIES THROUGH PARAMETER SPACE INTERPOLATION
A quantum computing system for optimizing instructions of a quantum circuit is configured to: select reference points in a parameter space of a family of gates that are executable by the quantum processor; identify edges in the parameter space connecting two reference points; compute a pulse vector for each reference point of the plurality of reference points; optimize the pulse vector for each reference point of the plurality of reference points based on the first pulse vector of each neighboring reference point connected to that reference point by an edge; receive a target operation from the quantum circuit for optimization; compute a second pulse vector for the target operation based on interpolating between a subset of reference points of the plurality of reference points; and executed the target operation on a quantum processor using the pulse vector for the target operation.
G06N 10/60 - Quantum algorithms, e.g. based on quantum optimisation, or quantum Fourier or Hadamard transforms
G06N 10/80 - Quantum programming, e.g. interfaces, languages or software-development kits for creating or handling programs capable of running on quantum computersPlatforms for simulating or accessing quantum computers, e.g. cloud-based quantum computing
G06N 10/40 - Physical realisations or architectures of quantum processors or components for manipulating qubits, e.g. qubit coupling or qubit control
A battery that cycles lithium ions includes a negative electrode, a positive electrode spaced apart from the negative electrode, and an electrolyte infiltrating the positive electrode. The positive electrode includes a high-voltage positive electrode material. The electrolyte includes an organosulfur compound, a fluorinated aromatic co-solvent, a solid electrolyte interphase (SEI) former, and at least one lithium salt.
In some aspects, provided herein are methods for treating a liver disease or associated condition in a subject, and related compositions. In some embodiments, the composition comprises lactulose and a commensal organism, such as a commensal bacterial species. In some embodiments, the patient has been determined to have a microbiome profile and metabolic profile in a fecal sample from the patient, which may be indicative that the patient will benefit from the treatment.
Provided herein are methods for the treatment or prevention of sickle cell crisis and symptoms associated therewith by the administration of low doses of tocilizumab to a subject. In particular embodiments, provided herein are pharmaceutical compositions comprising doses of 200 mg or less of tocilizumab and methods for the treatment or prevention of sickle cell crisis and symptoms or other conditions arising as a result thereof.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/00 - Medicinal preparations containing antigens or antibodies
27.
FUNCTIONALIZED NANOPARTICLES FOR THE CONTAINMENT AND CLEARANCE OF PATHOGENS
Functionalized nanoparticles for inhibiting or preventing pathogen infections (e.g., viral or bacterial infections, such as coronavirus infections) are described. The nanoparticles comprise a biodegradable polymer core and a lipid coating layer that is functionalized with a pathogen-binding receptor (e.g., an angiotensin-converting enzyme 2 (ACE2) receptor protein) and/or a pathogen-binding antibody or an antigen-binding fragment thereof (e.g., a virus-binding antibody or an antigen-binding fragment thereof). The nanoparticles are further functionalized by a phagocyte-specific ligand, e.g., a phosphatidylserine-containing lipid included in the lipid coating layer, to promote clearance of nanoparticle-bound pathogen. Methods of using the nanoparticles to treat or prevent pathogen infections (e.g., coronavirus infections) are also described.
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
Aspects of the present disclosure are directed to growth hormone receptor (GHR)-targeting polypeptides, including antibodies, antibody-drug conjugates, antibody fragments, antibody-like molecules, and chimeric receptors. Also disclosed herein are nucleic acids encoding for such GHR-targeting polypeptides and cells comprising such nucleic acids. Described are methods for treatment of acromegaly using GHR-targeting polypeptides.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
G01N 33/543 - ImmunoassayBiospecific binding assayMaterials therefor with an insoluble carrier for immobilising immunochemicals
Example embodiments allow for networks of hybrid controllers that can be computed efficiently and that can adapt to changes in the system(s) under control. Such a network includes at least one hybrid controller that includes a dynamic sub-controller and a learned system sub-controller. Information about the ongoing performance of the system under control is provided to both the hybrid controller and to an over-controller, which provides one or more control inputs to the hybrid controller in order to modify the ongoing operation of the hybrid controller. These inputs can include the set-point of the hybrid controller, one or more parameters of the dynamic controller, and an update rate or other parameter of the learned system controller. The over-controller can control multiple hybrid controllers (e.g., controlling respective sub-systems of an overall system) and can, itself, be a hybrid controller.
G05B 13/02 - Adaptive control systems, i.e. systems automatically adjusting themselves to have a performance which is optimum according to some preassigned criterion electric
G05B 13/04 - Adaptive control systems, i.e. systems automatically adjusting themselves to have a performance which is optimum according to some preassigned criterion electric involving the use of models or simulators
Antisense polynucleotides and their use in pharmaceutical compositions to induce exon skipping in targeted exons of the gamma sarcoglycan gene are provided, along with methods of preventing or treating dystrophic diseases such as Limb-Girdle Muscular Dystrophy.
C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
A61K 47/60 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
C12N 15/11 - DNA or RNA fragmentsModified forms thereof
31.
CYCLIC SULFUR CONTAINING ADDITIVE COMPOUNDS FOR HIGH VOLTAGE ENERGY STORAGE DEVICE ELECTROLYTES, AND PROCESSES THEREOF
Provided herein are cyclic sulfite and cyclic sulfate electrolyte additives and formulations for energy storage devices having improved performance. The improved performance may be realized as improved cycling stability at abusive testing conditions.
Systems and methods for generating and manipulating a guided electromagnetic wave in a waveguide are provided. The optical system includes a waveguide, such as a two-dimensional waveguide, and an optical element disposed adjacent the surface of the waveguide. To generate the guided electromagnetic wave, a converging laser beam is generated and coupled to the waveguide by steering the converging laser beam towards an edge of the waveguide and with a beam center trajectory approximately parallel to a surface of the waveguide.
Systems and methods for performing laser lithotripsy include introducing a lithotripsy medium containing nanoparticles into a body cavity comprising target obstructions and applying laser energy through the lithotripsy medium to disrupt the target obstructions. The nanoparticles may have diameters configured to enhance absorption efficiency of the laser energy. The nanoparticles may include organic polymers such as PEDOT: PSS or inorganic compounds such as indium tin oxide. Systems may include a laser source, a fluid delivery component configured to deliver the nanoparticle-containing lithotripsy medium, and an optical fiber for delivering laser energy. Methods of manufacturing lithotripsy media include selecting target wavelengths, synthesizing nanoparticles with corresponding absorption characteristics, and dispersing the nanoparticles at selected concentrations.
A61B 18/24 - Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves using laser the beam being directed along or through a flexible conduit, e.g. an optical fibreHand-pieces therefor with a catheter
A61B 17/22 - Implements for squeezing-off ulcers or the like on inner organs of the bodyImplements for scraping-out cavities of body organs, e.g. bonesSurgical instruments, devices or methods for invasive removal or destruction of calculus using mechanical vibrationsSurgical instruments, devices or methods for removing obstructions in blood vessels, not otherwise provided for
A61B 18/00 - Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
A61K 41/00 - Medicinal preparations obtained by treating materials with wave energy or particle radiation
A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
A lithium ion conducting membrane and methods of making the same. The membrane includes a polymeric matrix and a plurality of ion-conducting particles disposed within the polymeric matrix. An inorganic coating deposited in the polymeric matrix.
An actuator module includes a motor, a flywheel coupled to the motor and configured to be rotated by the motor, a power source, a controller coupled to the power source and the motor, and a housing enclosing the motor, the flywheel, the power source, and the controller. The controller is programmed to operate the motor using the power source in response to instructions received from a remote device.
A63H 30/04 - Electrical arrangements using wireless transmission
A63H 33/08 - Building blocks, strips or similar building parts to be assembled without the use of additional elements provided with complementary holes, grooves, or protuberances, e.g. dovetails
A method for forming lithium argyrodite composite powders includes providing within an atomic layer deposition (ALD) reactor lithium argyrodite powders of formula Li7−xBCh6−xXx, where 0
C23C 16/455 - Chemical coating by decomposition of gaseous compounds, without leaving reaction products of surface material in the coating, i.e. chemical vapour deposition [CVD] processes characterised by the method of coating characterised by the method used for introducing gases into the reaction chamber or for modifying gas flows in the reaction chamber
C23C 16/30 - Deposition of compounds, mixtures or solid solutions, e.g. borides, carbides, nitrides
A method of modifying a battery cathode material includes the steps of heating the battery cathode material to a temperature of about 250° C. to about 350° C.; while heating, exposing the battery cathode material to an organometallic gas; and purging the organometallic gas from the battery cathode material, wherein the method removes lithium carbonate from the cathode material surface.
H01M 4/36 - Selection of substances as active materials, active masses, active liquids
C01G 53/506 - Complex oxides containing nickel and at least one other metal element containing alkali metals, e.g. LiNiO2 containing manganese of the type (MnO2)n-, e.g. Li(NixMn1-x)O2 or Li(MyNixMn1-x-y)O2 containing lithium and cobalt with the molar ratio of nickel with respect to all the metals other than alkali metals higher than or equal to 0.5, e.g. Li(MzNixCoyMn1-x-y-z)O2 with x ≥ 0.5 with the molar ratio of nickel with respect to all the metals other than alkali metals higher than or equal to 0.8, e.g. Li(MzNixCoyMn1-x-y-z)O2 with x ≥ 0.8
H01M 4/525 - Selection of substances as active materials, active masses, active liquids of inorganic oxides or hydroxides of nickel, cobalt or iron of mixed oxides or hydroxides containing iron, cobalt or nickel for inserting or intercalating light metals, e.g. LiNiO2, LiCoO2 or LiCoOxFy
38.
HYDRATED SOLID IONIC CHANNELS FOR RARE EARTH ELEMENT SEPARATION AND RECOVERY
Methods of separating rare earth elements, such as lanthanides, from an aqueous solution that includes two or more different types of rare earth elements are provided. The methods use confined solid ionic channels in layered, mixed metal oxides to separate different rare earth ions based on hydration shell size, dehydration energy, binding affinity, and/or hydration phase transformations.
Because of its myeloid-specific expression, it was hypothesized that CD200R could provide both an inhibitory signal and a target for antigen delivery to antigen presenting cells if antigens are fused recombinantly to a soluble CD200. The examples demonstrate that immunological tolerance can be established using antigen-fused CD200 molecules, including CD200Fc- fused antigen. This tolerance was demonstrated by abrogating responses to immune challenge and induction of production of tolerogenic cytokines, including IL- 10. Accordingly, the polypeptides, compositions, and methods are useful for tolerization of any antigen, such as any antigen related to autoimmune conditions, allergy conditions, anti-drug immunity conditions, among others. Described here is a polypeptide comprising a CD200 polypeptide operatively linked to an antigen. Also provided is a nucleic acid encoding a polypeptide, an expression vector comprising a nucleic acid of the disclosure, host cells comprising a polypeptide of the disclosure. Also described are methods utilizing the polypeptides and compositions.
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
Systems and methods are disclosed for predicting the rise of different strains of viruses. A method comprises reading a genetic sequence of a first strain of a virus; identifying a plurality of residue indices in the genetic sequence; for each of the plurality of indices, assigning a predictor, the predictor configured to predict a residue for its assigned index based upon a residue of at least one other index, the predictors thereby forming a network; and determining, based on the network of predictors, a probability of transition of the first strain to a second strain.
G16H 50/80 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for detecting, monitoring or modelling epidemics or pandemics, e.g. flu
G16B 30/00 - ICT specially adapted for sequence analysis involving nucleotides or amino acids
41.
COMPOSITIONS AND METHODS RELATED TO MODIFICATION AND DETECTION OF PSEUDOURIDINE AND 5-HYDROXYMETHYLCYTOSINE
Aspects of the present disclosure are directed to methods and compositions for modification, detection, and quantification of pseudouridine and 5-hydroxymethylcytosine. Disclosed are methods for modification of pseudouridine and/or 5-hydroxymethylcytosine comprising bisulfite treatment under particular conditions. Further disclosed are compositions and kits comprising a bisulfite solution and instructions for use.
The Board of Trustees of the University of Illinois (USA)
Inventor
Weber, Christopher R.
Shen, Le
Khalili-Araghi, Fatemeh
Abstract
Provided is a method of treating a disorder mediated by claudin-2 and/or claudin-15, particularly an intestinal disorder, such as colitis or enteritis. The method comprises administering to the subject an effective amount of a compound of formula (I), formula (II), or otherwise as described herein or a pharmaceutically acceptable salt thereof. In another aspect, also provided are compounds of formula (Ia) and pharmaceutically acceptable salts thereof.
C07D 239/06 - Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
A61K 31/165 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
A61K 31/17 - Amides, e.g. hydroxamic acids having the group N—C(O)—N or N—C(S)—N, e.g. urea, thiourea, carmustine
A61K 31/343 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
A61K 31/4178 - 1,3-Diazoles not condensed and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
A61K 31/517 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
A61K 31/536 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and at least one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
C07D 233/24 - Radicals substituted by nitrogen atoms not forming part of a nitro radical
43.
MATERIALS AND METHODS FOR LARGE-SCALE SPATIAL TRANSCRIPTOMICS
The present disclosure relates to materials and methods for large-scale spatial transcriptomics. In particular, the disclosure provides methods for producing systems for spatial transcriptomics, along with materials and methods for determining the spatial location of a desired nucleic acid, such as RNA, within a tissue sample.
Provided herein are electrolyte additives and formulations for energy storage devices having improved performance. The improved performance may be realized as improved cycling stability at abusive testing conditions.
The current disclosure relates to nucleic acid therapeutics that target mRNA molecules and recruit translation machinery to increase the translation from the mRNA, thus increasing the protein product in a subject or cell. Accordingly, aspects of the disclosure relate to a chimeric nucleic acid comprising a targeting region and a translational activating region, wherein the translational activating region comprises at least one ribosome and/or translation factor binding site and wherein the targeting region comprises a region that is complementary to a target mRNA. Further described are circular nucleic acids comprising a targeting region and a translational activating region, wherein the translational activating region comprises at least one ribosome and/or translation factor binding site and wherein the targeting region comprises a region that is complementary to a target mRNA.
A structured illumination microscopy system includes a plurality of lights sources. Each light source emits an excitation beam. The excitation beams vary in wavelength. The system also includes a plurality of dichroic mirrors positioned to collimate the excitation beams emitted from the plurality of light sources into a multicolor beam. A blazed grating is positioned to receive the multicolor beam and to disperse the multicolor beam into a plurality of monochrome beams. The blazed grating directs the monochrome beams toward a digital micromirror device, which is positioned to receive the plurality of monochrome beams from the blazed grating and to direct the plurality of monochrome beams toward a sample. An image sensor is positioned between the digital micromirror device and the sample. The image sensor generates an image of the sample based at least in part on an interaction of the plurality of monochrome beams and the sample.
A coherence model predicts the coherence time of one spin qubit based on decoherence caused by a surrounding spin bath. This coherence model, which is constructed by performing cluster correlation expansion calculations of spin-bath-induced decoherence, includes a library of coherence time distributions over a parameter-space range. Using this library, maximum likelihood estimation is then performed on a set of experimental data, enabling the density of the spin bath and the dimensionality of the spin qubits to be determined, given certain geometrical constraints. Rather than relying on assumptions that average over interactions between bath spins and central qubit spins, the present embodiments simulate the dynamics of the entire interacting spin bath, producing a quantum mechanical characterization technique for quantum applications that can be incorporated into a feedforward synthesis loop.
G06N 10/40 - Physical realisations or architectures of quantum processors or components for manipulating qubits, e.g. qubit coupling or qubit control
G01N 24/12 - Investigating or analysing materials by the use of nuclear magnetic resonance, electron paramagnetic resonance or other spin effects by using double resonance
G06N 10/20 - Models of quantum computing, e.g. quantum circuits or universal quantum computers
G06F 30/3308 - Design verification, e.g. functional simulation or model checking using simulation
G06N 10/80 - Quantum programming, e.g. interfaces, languages or software-development kits for creating or handling programs capable of running on quantum computersPlatforms for simulating or accessing quantum computers, e.g. cloud-based quantum computing
G06N 10/00 - Quantum computing, i.e. information processing based on quantum-mechanical phenomena
Technologies for resource-efficient quantum error correction are disclosed. A quantum computer may include physical gate qubits, capable of general quantum gate operations such as single-qubit operations and nearest-neighbor two-qubit operations. Each physical qubit gate may be controllably coupled to a quantum memory. The quantum memory may have a lower per-gate error rate than the physical qubit gates as well as a lower per-qubit cost. Because errors accrue at a lower rate in the quantum memory, the physical gate qubits may be able to perform error correction for a large number of logical qubits in the quantum memory, even if the physical gate qubits have an error rate relatively close to an error threshold.
IOWA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (USA)
Inventor
Delferro, Massimiliano
Ferrandon, Magali S.
Poeppelmeier, Kenneth R.
Sadow, Aaron D.
Scott, Susannah
Lapointe, Anne M.
Coates, Geoffrey
Abstract
A method of upcycling polymers to useful hydrocarbon materials. A catalyst with nanoparticles on a substrate selectively docks and cleaves longer hydrocarbon chains over shorter hydrocarbon chains. The catalyst includes metal nanoparticles in an order array on a substrate.
Provided herein are methods of preparing an immunotherapeutic with enhanced efficacy by treating lymphocytes with a B-cell lymphoma 2 (BCL-2) inhibitor, immunotherapeutic compositions produced by the methods herein, and methods of treating cancer therewith.
Aspects of the present disclosure are directed to synthetic DNA binding peptides, as well as methods of generating such peptides and methods for use of such peptides in, for example, DNA binding, modifying gene expression, and treatment of various conditions such as cancer, fibrosis, and diabetes. Certain aspects provide synthetic DNA binding dimers comprising two modified bZIP peptides, each comprising a modified basic domain and a modified leucine zipper domain and linked via an interpeptide linker (e.g., a side-by-side interpeptide linker). Also disclosed are universal methods for generating high affinity synthetic DNA binding dimers from any bZIP protein.
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
Aspects of the present disclosure are directed to borealin-targeting polypeptides, including antibodies, antibody-drug conjugates, antibody fragments, antibody-like molecules, and chimeric receptors. Also disclosed herein are nucleic acids encoding for such borealin-targeting polypeptides and cells comprising such nucleic acids. Described are methods for detection, diagnosis, and treatment of cancer using borealin-targeting polypeptides.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells
C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
G01N 33/573 - ImmunoassayBiospecific binding assayMaterials therefor for enzymes or isoenzymes
G01N 33/58 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving labelled substances
54.
DESIGNING BACTERIAL COMMUNITIES USING MACHINE LEARNING
Methods, systems, and apparatus, including computer programs encoded on a computer storage medium, for training a machine learning model that is configured to process a model input that defines a bacterial community to generate a predicted score that predicts a performance of the bacterial community in performing a bacterial task. According to one aspect, a method comprises: generating data identifying a set of bacterial communities; obtaining, for each bacterial community, a target score for the bacterial community; generating a set of training examples, wherein each training example corresponds to a respective bacterial community and comprises: (i) a training input that identifies the bacterial strains included in the bacterial community, and (ii) the target score for the bacterial community; training the machine learning model on the set of training examples; and identifying one or more candidate bacterial communities for performing the bacterial task using the trained machine learning model.
The present disclosure provides macrocyclic and macrobicyclic peptides with secondary structures that are stabilized over the corresponding non-cyclic peptides. The macrocyclic and macrobicyclic peptides are formed from peptides with adduct-forming, complementary reactive side chain moieties.
A new type of multi-bit and energy-efficient magnetic memory based on current-driven, field-free, and highly controlled domain wall motion is disclosed. A meandering domain wall magnetic channel with precisely interspersed pinning regions provides the multi-bit capability. The magnetic free layer of the memory device has a perpendicular magnetic anisotropy and interfacial Dzyaloshinskii-Moriya interaction, so that spin-orbit torques induce efficient domain wall motion. Example pinning mechanisms of the domain wall corresponding to various magnetic memory cell designs are further disclosed, including a two-way switching mechanism and a four-way switching mechanism as examples. A synthetic antiferromagnetic stack is further designed to function as the free magnetic layer, giving rise to improvement in operation speed and reliability and reduction of the domain wall tilting.
G11C 11/155 - Digital stores characterised by the use of particular electric or magnetic storage elementsStorage elements therefor using magnetic elements using thin-film elements with cylindrical configuration
G11C 11/02 - Digital stores characterised by the use of particular electric or magnetic storage elementsStorage elements therefor using magnetic elements
G11C 11/16 - Digital stores characterised by the use of particular electric or magnetic storage elementsStorage elements therefor using magnetic elements using elements in which the storage effect is based on magnetic spin effect
57.
WEARABLE SENSOR SYSTEM FOR DETECTING AND MONITORING RESPIRATION
An example of a physiological monitoring system includes a sensor system configured to be worn by a subject. The sensor system can include a compliant substrate, a sensor array arranged on the compliant substrate, a sensor module, and an electronic control system communicatively coupled to the sensor system. The sensor system can be configured to obtain sensor data representing a physiology of the subject, and transmit the sensor data to the electronic control system. The sensor data can include one or more first audio signals generated by a plurality of microphones of the sensor array and one or more second audio signals generated by an ambient microphone of the sensor module. Further, the electronic control system can be configured to receive the sensor data from the sensor system and, pre-process the sensor data, which in turn can include generating a respiratory waveform based on the pre-processed sensor data.
Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. (Germany)
Inventor
Lengyel, Ernst
Mann, Matthias
Curtis, Marion
Coscia, Fabian
Abstract
The current disclosure relates to methods for treating ovarian cancer based on specific antigen expression of the cancer. Furthermore, the expressed antigen may be used in immunotherapeutic methods for treatment of the ovarian cancer. Aspects of the disclosure relate to immunotherapies targeting CT45 polypeptides, methods for treating ovarian cancer based on CT45 expression, and kits for detecting CT45 polypeptides and nucleotides.
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
A61K 31/337 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
A61K 31/555 - Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
A61K 31/706 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
The invention provides an automated method for isolating a targeted isotope, the method having the steps of supplying a dissolved uranium targets into a first reaction environment; precipitating non-targeted isotope within the first reaction environment transferring liquid phase targeted isotope to a second reaction environment; precipitating the liquid phase targeted isotope in the second reaction environment; dissolving the precipitated targeted isotope; transferring the dissolved targeted isotope to a third reaction environment; and precipitating non-targeted isotope (i.e., iodine), such that the targeted isotope remains in the solution. Also provided is an automated system for isolating isotopes, the system having a plurality of reaction environments adapted to pneumatically receive and disgorge reactants and products via remotely actuated valves positioned between each of the reaction environments.
G21G 1/00 - Arrangements for converting chemical elements by electromagnetic radiation, corpuscular radiation, or particle bombardment, e.g. producing radioactive isotopes
61.
COMPOSITIONS AND METHODS FOR REPLICON-MEDIATED GENE THERAPY
SindbisSindbis RNA replicons or Venezuelan equine encephalitis (VEE) replicons, can stabilize the longevity of the RNA replicon and can stabilize the expression of the cargo proteins encoded by the self-replicating RNA molecule or RNA replicon. Also disclosed herein are compositions and methods directed to the discovery that certain viral proteins, including viral proteins that repress internal cellular innate immunity, can stabilize the payload expression and replication of the replicons. Technologies provided herein provide stabilization mechanisms that can improve vaccines, gene therapies, and/or other gene delivery methods.
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
The present disclosure relates to combination treatments for cancer. Specifically, the present disclosures relates to combination treatment of neuroendocrine tumors with an inhibitor of estrogen signaling or a retinoid, and radiation therapy or targeted radionuclide therapy.
A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
A61K 31/502 - PyridazinesHydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
A61K 31/565 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. oestrane, oestradiol
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Aspects of the present disclosure are directed to at least methods and compositions for diagnosis and/or treatment of diseases associated with aberrant levels of m5C RNA, including but not limited chromatin associate RNA (caRNA). The disease may comprise cancer and/or pre-cancerous cells. The disease may be associated with mutations in a TET2 pathway, including but not limited to mutations in TET2, IDH1, IDH2, and/or ASXL1 encoding genes. Treatment of a disease may comprises administration of one or more inhibitors of MBD6, TET2, and/or NSUN2. Also provided herein are methods of treatment of a disease in an individual comprising administering one or more inhibitors of MBD6, TET2, and/or NSUN2 to the individual determined to have aberrant m5C RNA modifications.
A method can include providing two or more parts. The two or more parts can include a first part and a second part. The method can include disposing a source material between the first part and the second part. The method can include joining and densifying the first part and the second part by reacting a liquid with the source material.
A high-resolution x-ray reflectometer system that is for characterization of mirrors for use with advanced light sources and includes a table, arc, and sample stage. The table and arc may be made of the same material, in some configurations that material is granite. An x-ray source and detector are mounted on the arc. The arc is movable along the surface of the table in a first direction, and the sample stage is moveable on the table surface in a second direction, perpendicular to the first direction. The sample stage can accommodate a sample with a thickness of 5 cm or more. Vertical lifting stages at each end of the sample stage allow for independent height adjustment of the ends, allowing for tiling of the sample. An autocollimator is mounted at the apex of the arc to characterize the tilt of a sample on the sample stage.
G01N 23/20008 - Constructional details of analysers, e.g. characterised by X-ray source, detector or optical systemAccessories thereforPreparing specimens therefor
66.
COMPOSITIONS AND METHODS FOR DETERMINING PROTEIN INTERACTIONS
Embodiments of the disclosure may comprise a photo-dependent proximity labeling system comprising an activatable probe and a retrievable substrate. The activatable probe may be, for example, an integrin binding peptide operatively coupled to a lumichrome molecule, and the retrievable substrate may be, for example, a biotin phenol. In some aspects, the activatable probe is activatable by light, thereby inducing labeling of adjacent molecules with a retrievable substrate. Also disclosed are methods for labeling proteins, identifying protein interactions or binding partners, and methods for identifying a therapeutic target in an individual using a composition of the disclosure.
A method for coating a coolant metal on a ceramic substrate comprises modification of the substrate surface to provide an oxide free surface upon which the coolant metal is deposited.
Employing undulator devices as x-ray radiation sources requires high magnetic field strength and precision for generating high intensity, high coherence radiation. A magnetic field tunable undulator device is described. The undulator device includes a first magnet array disposed along a central axis of the undulator device, and a second magnet array disposed along the central axis, opposite the first magnetic array, across a gap distance. First and second structural keepers are respectively coupled to the first and second magnetic arrays to support positions of the first and second magnet arrays. A plurality of tuning elements are (i) disposed along the central axis, (ii) physically coupled to at least one of the first magnet array or the second magnet array, and (iii) configured to tune the magnetic field profile along the central axis between the first magnet array and the second magnet array.
Typical chemical vapor deposition (CVD) systems are unable to analyze a sample during CVD fabrication. A system and method for performing material deposition and in-situ analysis of a sample during CVD synthesis is described. The system includes a deposition chamber having an outer chamber wall surrounding a chamber volume and an inner sleeve disposed inside of the chamber volume with a buffer region between the outer chamber wall and the inner sleeve. A sample mount is disposed in the deposition volume to support a position and orientation of a sample in the deposition volume during CVD. Gas inlets and gas outlets are in fluid communication with the deposition chamber to respectively allow fluid to flow into, and out of, the deposition chamber. A thermal radiation source provides thermal radiation along a deposition axis to the sample disposed in the deposition volume.
C23C 16/48 - Chemical coating by decomposition of gaseous compounds, without leaving reaction products of surface material in the coating, i.e. chemical vapour deposition [CVD] processes characterised by the method of coating by irradiation, e.g. photolysis, radiolysis, particle radiation
C23C 16/54 - Apparatus specially adapted for continuous coating
G01N 23/20008 - Constructional details of analysers, e.g. characterised by X-ray source, detector or optical systemAccessories thereforPreparing specimens therefor
70.
SURFACE CLEANING, MODIFICATION AND DOPING OF ARGYRODITE TYPE SOLID ELECTROLYTES
A method for modifying argyrodite-type material. The argyrodite-type material is exposed to a fluorine precursor. The argyrodite-type material may have a carbonate coating that has formed, such as due to exposure to air, with such carbonate coating at least partially removed by exposure to the fluorine precursor. The argyrodite-type material may further be doped by fluorine after exposure to the precursor. Further, the argyrodite-type material may have a capping layer formed thereon.
C23C 16/44 - Chemical coating by decomposition of gaseous compounds, without leaving reaction products of surface material in the coating, i.e. chemical vapour deposition [CVD] processes characterised by the method of coating
C23C 16/455 - Chemical coating by decomposition of gaseous compounds, without leaving reaction products of surface material in the coating, i.e. chemical vapour deposition [CVD] processes characterised by the method of coating characterised by the method used for introducing gases into the reaction chamber or for modifying gas flows in the reaction chamber
71.
PREDICTING PROPERTIES OF BIOLOGICAL ENTITIES USING EVOLUTIONARY TREES
Methods, systems, and apparatus, including computer programs encoded on a computer storage medium, for predicting a property of an input biological entity. The system generates an evolutionary feature representation of the input biological entity based at least in part on an evolutionary tree, and processes a model input that comprises the evolutionary feature representation sing a machine learning model to generate the prediction for the property of the input biological entity.
A catalyst for selective hexane and/or butene formation from ethylene. The catalyst is formed by grafting Cr or Mn to an inorganic support. The grafted metal site is reduced, forming a catalyst that is selective for selective trimerization of ethylene to hexene and/or butene.
Systems and methods are provided herein for training a customized model. A method of constructing a customized generative model, comprising reading a plurality of synthetic images and associated latent representations; presenting each of the plurality of synthetic images to one or more users via a client computing platform; reading a plurality of inputs characterizing a plurality of values for a plurality of associated attributes of each of the plurality of synthetic images; based on the values of the associated attributes and the latent representations, training a regression model to predict the values of the attributes from the latent representations.
G06V 10/774 - Generating sets of training patternsBootstrap methods, e.g. bagging or boosting
G06V 10/766 - Arrangements for image or video recognition or understanding using pattern recognition or machine learning using regression, e.g. by projecting features on hyperplanes
G06V 10/82 - Arrangements for image or video recognition or understanding using pattern recognition or machine learning using neural networks
G06V 10/94 - Hardware or software architectures specially adapted for image or video understanding
74.
METHOD FOR HIGHLY SENSITIVE DNA METHYLATION ANALYSIS
Methods, compositions and kits are provided to amplify an amount of genomic methylated DNA that can be subsequently analyzed and/or sequenced. It has particular use with small amounts of DNA, including, but not limited to cell free DNA samples. In some embodiments, the ratio of polymerase and methyltransferase is controlled in order to provide maximum yields. In some embodiments, a dual primase/polymerase is used.
In aspects, the present disclosure provides a method of treating or preventing premature ovarian insufficiency or polycystic ovary syndrome in a female mammal, the method comprising, consisting essentially of, or consisting of administering to the female mammal an effective amount of (i) mesenchymal stem cells (MSCs) or secretome from MSCs, wherein the MSCs overexpress (a) miR144, (b) BMP-2, (c) TGFβ1, (d) IL-10, or (e) any combination of (a), (b), (c) and (d); (ii) exosomes produced by MSCs, wherein the MSCs overexpress (a) miR144, (b) BMP-2, (c) TGFβ1, (d) IL-10, or (e) any combination of (a), (b), (c) and (d); and/or (iii) exosomes comprising one or more effectors, wherein the one or more effectors comprises, consists essentially of, or consists of (a) miR144, (b) BMP-2, (c) TGFβ1, (d) IL-10, or (e) any combination of (a), (b), (c) and (d), and wherein the amount of the effector per exosome is greater than the amount of the effector per exosome when produced by unmodified MSCs. In aspects, the present disclosure provides a method of preparing MSCs, exosomes, and secretome. In aspects, the present disclosure provides a method of preventing chemotherapy-induced damage in a male mammal.
Provided herein are methods for extracting and separating metals from a mixture of metal oxides comprising: disposing a cathode comprising the mixture of metal oxides, a reducing electrode, and an anode in a solvent comprising a mixture of molten metal hydroxide salts; applying an electrical potential to a cathode, thereby reducing the mixture of metal oxides and forming a mixture of metals; selectively dissolving one or more metal ion species from the mixture of metals into the dried solvent; and applying a potential to the reducing electrode present in the dried solvent to reduce the dissolved metal ion species from the dried solvent to a respective pure metal or mixed metal.
A shredder for minimizing aggregation of whole batteries can include a shaft defining a longitudinal axis and a latitudinal axis. The shredder can include a plurality of teeth disposed on knives which fit on said shaft at an angle to the latitudinal axis selected from 0 degrees and 45 degrees. The teeth can have a first proximal end integrally molded to the shaft and a second free distal end.
H01M 10/54 - Reclaiming serviceable parts of waste accumulators
B02C 18/08 - Disintegrating by knives or other cutting or tearing members which chop material into fragmentsMincing machines or similar apparatus using worms or the like with rotating knives within vertical containers
B02C 18/14 - Disintegrating by knives or other cutting or tearing members which chop material into fragmentsMincing machines or similar apparatus using worms or the like with rotating knives within horizontal containers
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (USA)
THE UNIVERSITY OF CHICAGO (USA)
Inventor
Simon, Jonathan
Schuster, David I.
Taneja, Lavanya
Abstract
An optical resonator includes a plurality of mirrors positioned to reflect light along a closed path, thereby defining an optical axis. The optical resonator also includes one or more intracavity lenses positioned along the optical axis to establish a resonator mode whose waist that is located along the optical axis. The optical resonator also includes an intracavity nonlinear optical element that implements a nonlinear frequency-mixing process within the optical resonator. When input light is coupled into the optical resonator to excite the resonator mode, the intracavity nonlinear optical element nonlinearly converts at least some of the input light into nonlinearly generated light. This nonlinearly generated light may then be coupled out of the optical resonator, such as via transmission through one of the mirrors. In some embodiments, the waist is five microns or less. In some embodiments, the finesse of the optical resonator is 100 or less.
A non-aqueous electrolyte comprising a salt, a non-aqueous solvent, and a compound of Formula (I) or Formula (II) or Formula (III) or Formula (IV) or Formula (V):
A non-aqueous electrolyte comprising a salt, a non-aqueous solvent, and a compound of Formula (I) or Formula (II) or Formula (III) or Formula (IV) or Formula (V):
An electrochemical cell includes an anode comprising silicon and an electrolyte comprising a linear carbonate and vinylene carbonate in a concentration of about 11 wt. % to about 80 wt. % based on the weight of the electrolyte. The electrolyte is free of saturated cyclic carbonates conventionally used in lithium-ion batteries.
Employing undulator devices as x-ray radiation sources requires expensive and bulky support systems for operation, which are not robust and lead to limited ranges of generated radiation energies. A force-compensated undulator device is described. The device includes an undulator having first and second magnet arrays disposed along a central axis. The first magnet array is translatable along the central axis. The device further includes a compensator unit disposed adjacent to the first magnet array with the compensator unit having a first row of magnets disposed along a compensator axis with the compensator axis being parallel to the central axis, and a second row of magnets disposed along the compensator axis. The first row of magnets is translatable along the compensator axis. The compensator provides magnetic forces that neutralize the system dynamic magnetic forces generated by the undulator.
The present document relates to systems and methods that implement acoustofluidics to manipulate particles within a microfluidic system. The method comprising delivering the sample through a first microchannel, wherein the sample comprises a first population of entities having a first characteristic and a second population of entities having a second characteristic that is different than the first characteristic; applying an acoustic wave through at least a portion of the first microchannel, thereby generating displacement of at least a portion of the first and second populations traveling through the first microchannel by way of acoustic radiation force and acoustic streaming; and separating the sample into a first separated population and a second separated population, wherein the first separated population comprises a majority of entities having the first characteristic and wherein the second separated population comprises a majority of entities having the second characteristic.
Aspects of the present disclosure are directed to methods, compositions, and kits for detection and analysis of DNA and RNA cytosine methylation. Certain aspects include methods, compositions and kits useful in bisulfite sequencing of methylated nucleic acids, including methylated nucleic acids from low-input samples such as cell-free DNA and cell-free RNA. Also disclosed are methods and compositions for detection and quantification of 5-hydroxymethylcytosine in DNA.
A polymer comprising a plurality of repeat units of formula (I)
A polymer comprising a plurality of repeat units of formula (I)
A polymer comprising a plurality of repeat units of formula (I)
or formula (IV)
A polymer comprising a plurality of repeat units of formula (I)
or formula (IV)
A polymer comprising a plurality of repeat units of formula (I)
or formula (IV)
wherein each Ar1 and Ar4 is a unit comprising two or more aromatic groups; Ar1 comprises at least one cross-linkable group; Ar4 comprises a substituent selected from —SO3H, —CO2H, —PO3H2, and salts thereof; R1 and R2, and R7 and R8, are independently selected from C1-6 alkyl, C1-6 haloalkyl, C3-10 cycloalkyl, C3-10 heterocycloalkyl, aryl, and heteroaryl, each optionally substituted, or R1 and R2, or R7 and R8, together with the carbon atom to which they are attached, form a carbocycle or heterocycle, provided that at least one of R7 and R8 contains an amide group or at least one geminal pair of R7 and R8, together with the carbon atom to which they are attached, forms a carbocycle or heterocycle that contains an amide group; and membranes and membrane electrode assemblies including same.
C08G 10/00 - Condensation polymers of aldehydes or ketones with aromatic hydrocarbons or halogenated aromatic hydrocarbons only
B01J 39/05 - Processes using organic exchangers in the strongly acidic form
B01J 39/19 - Macromolecular compounds obtained otherwise than by reactions only involving unsaturated carbon-to-carbon bonds
B01J 41/05 - Processes using organic exchangers in the strongly basic form
B01J 41/13 - Macromolecular compounds obtained otherwise than by reactions only involving unsaturated carbon-to-carbon bonds
B01J 47/12 - Ion-exchange processes in generalApparatus therefor characterised by the use of ion-exchange material in the form of ribbons, filaments, fibres or sheets, e.g. membranes
H01M 8/1004 - Fuel cells with solid electrolytes characterised by membrane-electrode assemblies [MEA]
H01M 8/1027 - Polymeric electrolyte materials characterised by the chemical structure of the main chain of the ion-conducting polymer having carbon, oxygen and other atoms, e.g. sulfonated polyethersulfones [S-PES]
H01M 8/103 - Polymeric electrolyte materials characterised by the chemical structure of the main chain of the ion-conducting polymer having nitrogen, e.g. sulfonated polybenzimidazoles [S-PBI], polybenzimidazoles with phosphoric acid, sulfonated polyamides [S-PA] or sulfonated polyphosphazenes [S-PPh]
85.
COMPOSITION AND METHODS FOR TUMOR IMAGING AND TREATMENT
Radioisotope-labeled small molecule activity-based probes that target the cancer associated serine hydrolase neutral cholesterol ester hydrolase 1 (NCEH1) are described. The probes can undergo a reaction with the NCEH1, resulting in covalent bonding of a portion of the probe molecule to the NCEH1. Also described are methods of labeling NCEH1 in biological samples, such as cells or tissue, and methods of visualizing tumors using the radioisotope-labeled NCEH1 probes as tracer compounds, either alone or in combination with assessing the efficacy of a cancer treatment or potential cancer treatment.
C07C 271/48 - Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by singly-bound oxygen atoms
86.
ESTROGEN RECEPTOR ALPHA ANTAGONISTS AND USES THEREOF
The disclosure provides compounds of Formula I, or pharmaceutically acceptable salts thereof, wherein n, X1, and R'-R3 are defined herein: Also provided are pharmaceutical compositions comprising a compound disclosed herein, methods of inhibiting estrogen receptor alpha (ERa), methods of treating an estrogen- mediated disease in a subject requiring inhibition of estrogen receptor (ER) alpha (ERa), methods of treating one or more symptoms of menopause in a subject in need thereof, and methods of treating one or more side effects of hormone replacement therapy.
A61K 31/395 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
A61K 31/435 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
A61K 31/4353 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
To address the need in the art, the inventors have comprehensively characterized Aspects of the disclosure relate to novel antibody and antigen binding fragments. Further aspects relate to polypeptides comprising the antigen binding fragment(s) of the disclosure, and compositions comprising the polypeptides, antibodies, and/or antigen binding fragments of the disclosure. Also described are nucleic acids encoding an antibody or antigen binding fragment of the disclosure.
Provided herein are depolymerizable thermally activated delayed fluorescence polymers with exceptional light-emitting properties and programmable depolymerization under specific stressors.
Lithium-ion cells including fluoroether electrolytes and configured to promote lithium intercalation and (de)intercalation within graphite without fluoroether co-intercalation are provided. Processes for preparing the lithium-ion cells are further provided.
H01M 10/0525 - Rocking-chair batteries, i.e. batteries with lithium insertion or intercalation in both electrodesLithium-ion batteries
H01M 4/02 - Electrodes composed of, or comprising, active material
H01M 4/38 - Selection of substances as active materials, active masses, active liquids of elements or alloys
H01M 4/58 - Selection of substances as active materials, active masses, active liquids of inorganic compounds other than oxides or hydroxides, e.g. sulfides, selenides, tellurides, halogenides or LiCoFySelection of substances as active materials, active masses, active liquids of polyanionic structures, e.g. phosphates, silicates or borates
H01M 10/0568 - Liquid materials characterised by the solutes
H01M 10/0569 - Liquid materials characterised by the solvents
Systems and methods for generating and manipulating a guided electromagnetic wave in a waveguide are provided. The optical system includes a waveguide, such as a two-dimensional waveguide, and an optical element disposed adjacent the surface of the waveguide. To generate the guided electromagnetic wave, a converging laser beam is generated and coupled to the waveguide by steering the converging laser beam towards an edge of the waveguide and with a beam center trajectory approximately parallel to a surface of the waveguide.
Lymphatic, nervous, and tumoral tissues, among others, exhibit physiology that emerges from three-dimensional interactions between genetically unique cells. A technology capable of volumetrically imaging genotypes and morphologies in a single de novo measurement would therefore provide a critical view into the biological complexity of living systems. The present disclosure achieves this by extending DNA microscopy, an imaging modality that encodes a spatio-genetic map of a specimen via a massive distributed network of DNA molecules inside it, to three dimensions and multiple length scales in developing zebrafish embryos.
The present disclosure concerns immunomodulatory compositions and methods of use for enhancing response to an antigen (e.g., in a vaccine), an immunotherapy (e.g., a cancer immunotherapy), or other immune stimulation. The disclosure describes immunomodulators having reduced toxicity and improved immune response compared with existing adjuvants. Further disclosed are methods for improving an immune response to a vaccine antigen, cancer immunotherapeutic, or other immune stimulating agent. The disclosure describes dimeric and polymeric immunomodulators comprising one or more pattern recognition receptor (PRR) agonist moieties and one or more NF-κB inhibitor moieties.
A61K 39/21 - Retroviridae, e.g. equine infectious anemia virus
A61K 39/215 - Coronaviridae, e.g. avian infectious bronchitis virus
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
The invention provides a method for fabricating x-ray focusing optics, the method comprising supplying a first cathode forming a first channel, inserting a substrate within the channel; and charging the first cathode to sputter first cathode material to a surface defining the substrate, thereby forming a first zone film onto the surface. Also provided is a monolithic X-ray diffraction lens having sub 10 nanometer resolutions, the lens comprising a substrate overlaid with discrete regions of metal, the regions integrally molded with the substrate.
G21K 1/06 - Arrangements for handling particles or ionising radiation, e.g. focusing or moderating using diffraction, refraction, or reflection, e.g. monochromators
C23C 14/04 - Coating on selected surface areas, e.g. using masks
94.
CONCENTRATED SOLAR POWER ELECTRIC POWER PLANT HEAT EXCHANGE MODULE
An additively manufactured heat exchanger adapted for use in extreme environments, such as a concentrated solar power (CSP) electric power plant. The heat exchanger receives a liquid heat transfer fluid at a high temperature and high pressure. The heat exchanger efficiently exchanges heat with a working fluid flowing in a cross-flow or a counter-flow configuration. A first set of channels of the heat exchanger receives liquid heat transfer fluid, such as corrosive molten salt, and a second set of channels receives working fluid, such as super critical carbon dioxide. The heat exchanger transfers heat from the liquid heat transfer fluid to the working fluid.
B22F 1/10 - Metallic powder containing lubricating or binding agentsMetallic powder containing organic material
B33Y 80/00 - Products made by additive manufacturing
F28F 1/10 - Tubular elements or assemblies thereof with means for increasing heat-transfer area, e.g. with fins, with projections, with recesses
F28F 21/04 - Constructions of heat-exchange apparatus characterised by the selection of particular materials of ceramicConstructions of heat-exchange apparatus characterised by the selection of particular materials of concreteConstructions of heat-exchange apparatus characterised by the selection of particular materials of natural stone
F28F 21/08 - Constructions of heat-exchange apparatus characterised by the selection of particular materials of metal
Aspects of the present disclosure are directed to methods and compositions for generation of antigen-specific regulatory T cells. Certain aspects relate to methods and compositions for generating tolerogenic antigen presenting cells, including tolerogenic dendritic cells. The present disclosure includes compositions, including nanocarrier compositions, comprising TLR agonists, and immunosuppressive agents and optionally an antigen. Also disclosed are methods for use of such compositions in generation of tolerogenic antigen presenting cells and treatment of certain conditions, including autoimmune and inflammatory conditions.
A61K 31/366 - Lactones having six-membered rings, e.g. delta-lactones
A61K 31/381 - Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
A61K 31/575 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
96.
POLYPEPTIDES FOR DETECTION AND TREATMENT OF CORONAVIRUS INFECTION
Here, the inventors report that natural WT SARS-CoV-2 infection induces memory B cells expressing potently neutralizing antibodies against VOCs. Moreover, natural WT infection largely induced antibodies against spike epitopes outside of the RBD, most of which were non-neutralizing against WT and VOCs. Additionally. RBD-binding antibodies could be categorized into 3 distinct classes based on their binding profiles against RBD mutant constructs. The inventors identified VOC-neutralizing antibodies against three distinct regions of the spike protein, including the two epitopes on the RBD and one epitope in the NTD. Together, this study identifies that natural WT infection induces memory B cells that can produce neutralizing antibodies against recent SARS-CoV-2 VOCs and have the potential to be recalled by vaccination.
C07K 16/10 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
A61K 31/675 - Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A lithium-sulfur battery providing stable, high energy density includes a cathode including sulfur, an anode including lithium metal, and an electrolyte including non-aqueous solvent and an additive including a fluorinated borate or a fluorinated borane; and lithium bis(nonafluorobutanesulfonyl)imide (LiNFBSI).
Aspects of the present disclosure are directed to survivin-targeting polypeptides, including antibodies, antibody-drug conjugates, antibody fragments, antibody-like molecules, and chimeric receptors. Also disclosed herein are nucleic acids encoding for such survivin-targeting polypeptides and cells comprising such nucleic acids. Described are methods for detection, diagnosis, and treatment of cancer using survivin-targeting polypeptides.
A process for charging a discharged electrochemical cell includes applying a voltage bias to the discharged electrochemical cell; and illuminating the cathode, the anode, or both the cathode and the anode with light having a narrow band of wavelengths corresponding to the respective band gaps of the electrode active materials.
H01M 4/485 - Selection of substances as active materials, active masses, active liquids of inorganic oxides or hydroxides of mixed oxides or hydroxides for inserting or intercalating light metals, e.g. LiTi2O4 or LiTi2OxFy
H01M 4/505 - Selection of substances as active materials, active masses, active liquids of inorganic oxides or hydroxides of manganese of mixed oxides or hydroxides containing manganese for inserting or intercalating light metals, e.g. LiMn2O4 or LiMn2OxFy
H01M 10/0525 - Rocking-chair batteries, i.e. batteries with lithium insertion or intercalation in both electrodesLithium-ion batteries
Systems and methods are disclosed for electronic monitoring. A method of electronic monitoring comprises receiving a location of a participant, receiving data associated with the participant, and determining an alert level for the participant based on the data and the location of the participant.
